Department of Cell Biology, Physiology, and Immunology, University of Córdoba, Avenida Menéndez Pidal s/n, 14004 Córdoba, Spain.
Endocrinology. 2010 Feb;151(2):722-30. doi: 10.1210/en.2009-0803. Epub 2009 Dec 1.
Kisspeptins (Kp) have recently emerged as master regulators of the reproductive axis and among the most potent elicitors of GnRH-gonadotropin secretion. Despite their paramount importance in reproductive physiology and their potential therapeutic implications, development of Kp antagonists has remained elusive, and only recently has the first compound with the ability to block Kp actions in vitro and in vivo, namely p234, been reported. However, previous in vivo studies all used acute central injections, whereas characterization of the effects of the antagonist after continuous or systemic administration, which poses pharmacological challenges, is still pending. We report herein a comprehensive series of analyses on the impact of continuous intracerebroventricular infusion of p234 on puberty onset and the preovulatory surge of gonadotropins in the female rat. In addition, the effects of systemic (ip) administration of a tagged p234-penetratin, with a predicted higher permeability at the blood-brain barrier, on Kp-10 induced gonadotropin secretion were evaluated. Central infusion of p234 to pubertal females delayed vaginal opening and decreased uterine and ovarian weights at the expected time of puberty, without affecting body weight. Likewise, chronic intracerebroventricular administration of p234 for 4 d prevented the preovulatory surges of LH and FSH. In addition, systemic (ip) administration of p234-penetratin significantly attenuated acute LH and FSH responses to Kp-10, either after intracerebroventricular or ip injection of Kp. Our data document the validity of p234 for antagonizing Kp actions in vivo and provide direct experimental evidence for the important role of Kp signaling in the key events of female reproduction, such as puberty onset and the preovulatory surge of gonadotropins.
kisspeptins (kp) 最近被认为是生殖轴的主要调节因子,也是促性腺激素释放激素-促性腺激素分泌的最有效刺激物之一。尽管它们在生殖生理学中具有至关重要的作用,并且具有潜在的治疗意义,但 kp 拮抗剂的开发仍然难以捉摸,直到最近才报道了第一种具有体外和体内阻断 kp 作用的化合物,即 p234。然而,以前的体内研究都使用了急性中枢注射,而对拮抗剂在连续或全身给药后的作用的特征描述,这带来了药理学上的挑战,仍有待进行。本文报道了一系列关于 p234 持续脑室内输注对青春期启动和雌性大鼠促性腺激素排卵前激增的影响的综合分析。此外,还评估了一种标记的 p234-穿透肽(预计在血脑屏障中有更高的通透性)对 kp-10 诱导的促性腺激素分泌的系统(ip)给药的影响。向青春期雌性大鼠脑室内输注 p234 可延迟阴道开口,并在青春期预期时间降低子宫和卵巢重量,而不影响体重。同样,p234 慢性脑室内给药 4 天可阻止 LH 和 FSH 的排卵前激增。此外,p234-穿透肽的系统(ip)给药可显著减弱 kp-10 对急性 LH 和 FSH 反应,无论是通过脑室内还是 ip 注射 kp 引起的。我们的数据证明了 p234 在体内拮抗 kp 作用的有效性,并为 kp 信号在女性生殖的关键事件(如青春期启动和促性腺激素排卵前激增)中的重要作用提供了直接的实验证据。